These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 23895690)

  • 21. A novel polymyxin derivative that lacks the fatty acid tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane.
    Vaara M; Siikanen O; Apajalahti J; Fox J; Frimodt-Møller N; He H; Poudyal A; Li J; Nation RL; Vaara T
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3341-6. PubMed ID: 20479195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Causes of polymyxin treatment failure and new derivatives to fill the gap.
    Chiu S; Hancock AM; Schofner BW; Sniezek KJ; Soto-Echevarria N; Leon G; Sivaloganathan DM; Wan X; Brynildsen MP
    J Antibiot (Tokyo); 2022 Nov; 75(11):593-609. PubMed ID: 36123537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymyxin antibiotics for gram-negative infections.
    Arnold TM; Forrest GN; Messmer KJ
    Am J Health Syst Pharm; 2007 Apr; 64(8):819-26. PubMed ID: 17420197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections.
    Magee TV; Brown MF; Starr JT; Ackley DC; Abramite JA; Aubrecht J; Butler A; Crandon JL; Dib-Hajj F; Flanagan ME; Granskog K; Hardink JR; Huband MD; Irvine R; Kuhn M; Leach KL; Li B; Lin J; Luke DR; MacVane SH; Miller AA; McCurdy S; McKim JM; Nicolau DP; Nguyen TT; Noe MC; O'Donnell JP; Seibel SB; Shen Y; Stepan AF; Tomaras AP; Wilga PC; Zhang L; Xu J; Chen JM
    J Med Chem; 2013 Jun; 56(12):5079-93. PubMed ID: 23735048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibacterial mechanisms of polymyxin and bacterial resistance.
    Yu Z; Qin W; Lin J; Fang S; Qiu J
    Biomed Res Int; 2015; 2015():679109. PubMed ID: 25664322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resistance to polymyxins: Mechanisms, frequency and treatment options.
    Falagas ME; Rafailidis PI; Matthaiou DK
    Drug Resist Updat; 2010; 13(4-5):132-8. PubMed ID: 20843473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel polymyxin derivatives are effective in treating experimental Escherichia coli peritoneal infection in mice.
    Vingsbo Lundberg C; Vaara T; Frimodt-Møller N; Vaara M
    J Antimicrob Chemother; 2010 May; 65(5):981-5. PubMed ID: 20233777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rational Combinations of Polymyxins with Other Antibiotics.
    Bergen PJ; Smith NM; Bedard TB; Bulman ZP; Cha R; Tsuji BT
    Adv Exp Med Biol; 2019; 1145():251-288. PubMed ID: 31364082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.
    Falagas ME; Kasiakou SK
    Clin Infect Dis; 2005 May; 40(9):1333-41. PubMed ID: 15825037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ask the experts: how to curb antibiotic resistance and plug the antibiotics gap?
    Piddock L; Garneau-Tsodikova S; Garner C
    Future Med Chem; 2016 Jun; 8(10):1027-32. PubMed ID: 27327784
    [No Abstract]   [Full Text] [Related]  

  • 31. PmxPred: A data-driven approach for the identification of active polymyxin analogues against gram-negative bacteria.
    Wang X; Patil N; Li F; Wang Z; Zhan H; Schmidt D; Thompson P; Guo Y; Landersdorfer CB; Shen HH; Peleg AY; Li J; Song J
    Comput Biol Med; 2024 Jan; 168():107681. PubMed ID: 37992470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can octapeptin antibiotics combat extensively drug-resistant (XDR) bacteria?
    Blaskovich MAT; Pitt ME; Elliott AG; Cooper MA
    Expert Rev Anti Infect Ther; 2018 Jun; 16(6):485-499. PubMed ID: 29848132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polymyxins: Mode of Action.
    Li Z; Velkov T
    Adv Exp Med Biol; 2019; 1145():37-54. PubMed ID: 31364070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.
    Poirel L; Jayol A; Nordmann P
    Clin Microbiol Rev; 2017 Apr; 30(2):557-596. PubMed ID: 28275006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polymyxin derivatives: a patent evaluation (WO2012168820).
    Wu H; Teng P; Niu Y; Li Q; Cai J
    Expert Opin Ther Pat; 2013 Aug; 23(8):1075-81. PubMed ID: 23806121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.
    Bergen PJ; Bulman ZP; Saju S; Bulitta JB; Landersdorfer C; Forrest A; Li J; Nation RL; Tsuji BT
    Pharmacotherapy; 2015 Jan; 35(1):34-42. PubMed ID: 25630411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical translation of polymyxin-based combination therapy: Facts, challenges and future opportunities.
    Zhang X; Guo F; Shao H; Zheng X
    J Infect; 2017 Feb; 74(2):118-130. PubMed ID: 27998750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Polymyxins: wisdom does not always come with age.
    Kassamali Z; Rotschafer JC; Jones RN; Prince RA; Danziger LH
    Clin Infect Dis; 2013 Sep; 57(6):877-83. PubMed ID: 23728146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure--activity relationships of polymyxin antibiotics.
    Velkov T; Thompson PE; Nation RL; Li J
    J Med Chem; 2010 Mar; 53(5):1898-916. PubMed ID: 19874036
    [No Abstract]   [Full Text] [Related]  

  • 40. Inactivation of Polymyxin by Hydrolytic Mechanism.
    Yin J; Wang G; Cheng D; Fu J; Qiu J; Yu Z
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30936102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.